CA Patent

CA3182026A1 — Trem compositions and methods relating thereto

Assigned to Flagship Pioneering Innovations VI Inc · Expires 2021-12-02 · 4y expired

What this patent protects

The disclosure relates generally to uses of tRNA-based effector molecules having a non-naturally occurring modification.

USPTO Abstract

The disclosure relates generally to uses of tRNA-based effector molecules having a non-naturally occurring modification.

Drugs covered by this patent

Patent Metadata

Patent number
CA3182026A1
Jurisdiction
CA
Classification
—
Expires
2021-12-02
Drug substance claim
No
Drug product claim
No
Assignee
Flagship Pioneering Innovations VI Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.